Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Deogaonkar, Rohan ^a   Hutubessy, Raymond ^b   Van Der Putten, Inge ^b,c   Evers, Silvia ^c   Jit, Mark ^a,d,e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost effectiveness analysis; Developing countries; Economic evaluations; Externalities; Immunization; Low and middle income countries; Vaccines

Indexed keywords

COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; HUMAN; REVIEW; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; VACCINATION;

EID: 84867417247     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-878     Document Type: Review

References (48)

1. Vaccines: past, present and future. Plotkin SA, Nat Med 2005 11 Suppl 4 5 S11 15812490
2. Partially wrong? Partial equilibrium and the health economic analysis of public health emergencies of international concern. Beutels P, Edmunds WJ, Smith RD, Health Econ 2008 17 1317 1322 10.1002/hec.1339 18246542
3. 30 years of pharmaceutical cost-utility analysis, growth, diversity and methodological improvement. Neumann PJ, Fang C, Cohen JT, Pharmacoeconomics 2009 27 861 872 10.2165/11312720-000000000-00000 19803540
4. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenza type b vaccine. Bärnighausen T, Bloom DE, Canning D, Friedman A, Levine OS, O'Brien J, Privor-Dumm L, Walker D, Vaccine 2011 29 2371 2380 10.1016/j.vaccine.2010.11.090 21159324
5. The Value of Vaccination. Bloom DE, Adv Exp Med Biol 2011 697 1 8 10.1007/978-1-4419-7185-2-1 21120715
6. Investing in Children's Health: What Are the Economic Benefits? Belli P, Bustreo F, Preker A, Bulletin of the World Health Organization 2005 83 777 784 16283055
7. Hauck K, Smith PC, Goddard M, The economics of priority setting for health care: a literature review Washington DC, USA: International Bank for Reconstruction and Development 2004
8. Cost-effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Shillcutt SD, Walker DG, Goodman CA, Mills AJ, Pharmacoeconomics 2009 27 903 917 10.2165/10899580-000000000-00000 19888791
9. World Health Organization, Guide to identifying the economic consequences of disease and injury Geneva: WHO 2009
10. How much of cross-country income variation is explained by health? Shastry GK, Weil DN, Journal of the European Economic Association 2002 1 387 396
11. The value of vaccination. Bloom DE, Canning D, Weston M, World Economics 2005 6 15 39
12. Demographic transition, income distribution, and economic growth. Dahan M, Tsiddon D, Journal of Economic Growth 1998 3 29 52 10.1023/A:1009769930916
13. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Jit M, Brisson M, Pharmacoeconomics 2011 29 371 386 10.2165/11539960-000000000-00000 21504239
14. Willingness to pay for hypothetical malaria vaccines in rural Burkina Faso. Sauerborn R, Gbanjou A, Dong H, Przyborski JM, Lancer M, Scand J Public Health 2005 33 146 150 (2005) 15823976
15. Private demand for cholera vaccines in Beira, Mozambique. Lucas MES, Jeuland M, Deen J, Lazaro N, et al. Vaccine 2007 2007 25 2599 2609
16. The demand for a dengue vaccine: A contingent valuation survey in metro Manila. Palanca-Tan R, Vaccine 2008 26 914 923 2008 10.1016/j.vaccine.2007.12. 011 18206277
17. Private demand for cholera vaccines in Hue, Vietnam. Kim D, Canh DG, Poulos C, Thoa LTK, et al. Value Health 2008 11 119 128 10.1111/j.1524-4733. 2007.00220.x 18237366
18. Household demand for preventive HIV/AIDS vaccines in Thailand: Do husbands' and wives' preferences differ? Whittington D, Suraratdecha C, Poulos C, Ainsworth M, Prabhu V, Tangcharoensathien V, Value Health 2008 11 965 974 10.1111/j.1524-4733.2007.00312.x 18194396
19. Rethinking cholera and typhoid vaccination policies for the poor: Private demand in Kolkata, India. Whittington D, Sur D, Cook J, Chatterjee S, et al. World Dev 2009 37 399 409 10.1016/j.worlddev.2008.04.002
20. Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. Cook J, Jeuland M, Maskery B, Lauria D, et al. J Policy Anal Manage 2009 28 6 28 10.1002/pam.20401 19090047
21. Willingess to pay for three hypothetical malaria vaccines in Nigeria. Udezi WA, Usifoh CO, Ihimekpen OO, Clin Ther 2010 32 1533 1544 10.1016/j.clinthera.2010.07.018 20728765
22. During the 'Decade of Vaccines' the lives of 6.4 million children valued at $231 billion could be saved. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, Walker DG, Levine OS, Health Aff 2011 30 1010 1020 10.1377/hlthaff.2011.0381
23. Economic burden of cholera in the WHO African region. Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG, BMC International Health and Human Rights 2009 9 8 10.1186/1472-698X-9-8 19405948
24. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. Smith RD, Keogh-Brown MR, Barnett T, Tait J, BMJ 2009 339 4571 10.1136/bmj.b4571 19926697
25. Barham T, Calimeris L, Long-term effects of family planning and child health interventions on adolescent cognition: Evidence from Matlab in Bangladesh University of Colorado: Health and Society program, Working paper 2008
26. Kumar S, Childhood immunization, mortality and human capital accumulation: Micro-evidence from India University of Houston: Harvard Centre for Population and Development Studies, Working paper 2009 http://mpra.ub.uni- muenchen.de/31806/
27. Assessing economic benefits for government and society attributed to malaria investment strategies: An exploratory analysis based on malaria vaccination. Connolly M, Constenla D, Proceedings of The Multilateral Initiative on Malaria 2009 www.gmasoln.com/downloads/Malaria.pdf
28. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Bishai D, Koenig M, Khan MA, Health Econ 2003 12 415 419 10.1002/hec.732 12720258
29. Comparative impact assessment of child pneumonia interventions. Niessen L, ten Hove A, Hilderink H, Weber M, Mulholland K, Ezzati M, Bull World Health Organ 2009 87 472 480 10.2471/BLT.08.050872 19565126
30. Economic analysis of the global polio eradication initiative. Tebbens RJD, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM, Vaccine 2011 29 334 343
31. Estimated economic benefits during the 'Decade of Vaccines' include treatment savings, gains in labor productivity. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, Walker DG, Levine OS, Health Aff 2011 30 1021 1028 10.1377/hlthaff.2011.0382
32. Bloom DE, Canning D, Seiguer E, The effect of vaccination on children's physical and cognitive development in the Philippines Harvard school of public health: Working paper 2011 http://www.hsph.harvard.edu/pgda/working.htm 23100246
33. Vaccination externalities. Boulier BL, Datta TS, Goldfarb RS, The B.E. Journal of Economic Analysis & Policy 2007 7 rticle 23 22977309
34. The cost-effectivness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J, J Gastroenterology 2007 42 152 160 10.1007/s00535-006-1984-x
35. Cost-effectiveness of new-generation oral cholera vaccines: A multisite analysis. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, Value Health 2009 12 899 908 10.1111/j.1524-4733.2009.00562.x 19824189
36. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. Kim SY, Lee G, Goldie SJ, BMC Infect Dis 2010 10 260 278 10.1186/1471-2334-10- 260 20815900
37. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Giglio ND, Cane AD, Micone P, Gentile A, Vaccine 2010 28 2302 2310 10.1016/j.vaccine.2009.12.070 20064478
38. Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil. Vespa G, Constenla DO, Pepe C, Safadi MA, Berezin E, Moraes JC, Campos CAH, Araujo DV, Andrade ASS, Pan Am J Public Health 2009 26 518 528 10.1590/S1020-49892009001200007
39. A Cost-Benefit Analysis of Cholera Vaccination Programs in Beira, Mozambique. Jeuland M, Lucas M, Clemens J, Whittington D, World Bank Econ Rev 2009 23 235 267 10.1093/wber/lhp006
40. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs. Jeuland M, Whittington D, Vaccine 2009 27 3109 3120 10.1016/j.vaccine.2009.02.104 19428925
41. Controlling endemic cholera with oral vaccines. Longini IM, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD, PLoS Med 2007 4 1776 1783
42. The impact of immunization on the association between poverty and child survival: Evidence from Kassena-Nankana district of northern Ghana. Bawah AA, Phillips JF, Adjuik M, Vaughan-Smith M, Macleod B, Binka FN, Scand J Public Health 2010 38 95 103 10.1177/1403494809352532 19884162
43. The Economic Costs of Illness: A Replication and Update. Rice DP, Hodgson TA, Kopstein AN, Health Care Financ Rev 1985 7 61 80 No. 1, Fall 1985 10311399
44. The friction cost method for measuring indirect costs of disease. Koopmanschap A, Rutten F, van Ineveld B, van Roijen L, J Health Econs 1995 14 171 189 10.1016/0167-6296(94)00044-5
45. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Molinari NA, Ortega-Sanchez IR, Messonier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB, Vaccine 2007 25 5086 5096 10.1016/j.vaccine.2007.03.046 17544181
46. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R, BMC Med 2011 9 54 10.1186/1741-7015-9-54 21569406
47. The societal value of vaccination in developing countries. Shearley AE, Vaccine 1999 17 109 S112 10559542
48. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands. Keogh-Brown MR, Smith RD, Edmunds JW, Beutels P, Eur J Health Econs 2010 11 543 554 10.1007/s10198-009-0210-1